Abbott Laboratories Corporation

Cancer Research Campaign Technology Limited

Aston University

Other

Epx Research Limited

Nestec S.a.

Takeda Chemical Industries, Inc.

Ashton University

Michael John Tisdale

Pradip Mukerji

Jeffrey H Baxter

Anne C Voss

Washington Odur Ayuko

Eric Lattmann

Susan A Beck

Steven Russell

Shinji Terao

Norman Alan Greenberg

Kevin Burke Miller

Penio Todorov

Stacey Marie Wyke

Penio T Todorov

Helen Laura Eley

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of Zn-&#x3b1;-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as &#x3b2; adrenergin receptor agonists, &#x3b2; adrenergin receptor antagonists, and/or glycemic control agents.

[object Object]

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-&#x3b1;-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as &#x3b2; adrenergin receptor agonists, &#x3b2; adrenergin receptor antagonists, and/or glycemic control agents.

Glycoproteins having lipid mobilizing properties and therapeutic uses thereof

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate

The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof. The invention further provides nutritional products for such administration, including orally-administrable nutritional products.

Methods for the treatment of muscle loss

HMB uses thereof

The invention characterises and provides a receptor for Proteolysis Inducing Factor (PIF) and associated methods and materials employing the same. These have utility, for example, in the provision of treatments for cachexia.

Antibodies to proteolysis inducing factor (PIF) receptor and methods of use thereof

This invention relates to certain dioxodihydropyridine derivatives and certain methacrylic acid and furan derivative precursors thereof, processes for their preparation, pharmaceutical compositions containing such compounds and their use as anti-proliferative agents, especially tumour growth inhibitors and anti-cancer agents, antibiotics and/or antiviral agents.

Antiproliferative agents

A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-&#x3b1;-glycoprotein, or of a fragment thereof having an apparent molecular mass Mgreater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.

Glycoproteins having lipid mobilising properties and therapeutic applications thereof

This invention relates to certain dioxodihydropyridine derivatives and certain methacrylic acid and furan derivative precursors thereof, processes for their preparation, pharmaceutical compositions containing such compounds and their use as anti-proliferative agents, especially tumor growth inhibitors and anti-cancer agents, antibiotics and/or antiviral agents.

A biologically active lipid mobilizing agent for use in therapy is disclosed which has the properties and characteristics of a Zn-&#x3b1;-glycoprotein, or of a fragment thereof having an apparent molecular mass Mgreater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.

Glycoproteins having lipid mobilizing properties and therapeutic applications thereof

Use of quinone and hydroquinone derivatives for the treatment of cachexia

The use of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid or EPA, preferably substantially free of any other polyunsaturated fatty acids, is disclosed for making up medical preparations or compositions for the treatment of cachexia by inhibiting lipolytic activity of biologically active lipolytic agents present in body fluids and the activity of the enzyme guanidinobenzoatase, as well as for reducing abnormal cAMP levels in cells of adipose tissue in mammals, produced by lipolytic or fat mobilizing substances.

Eicosapentaenoic acid used to treat cachexia

A biologically active lipolytic factor having an average molecular weight substantially less than 5000 daltons and comprising active molecular species having molecular weights of about 3000 daltons, 1500 daltons and 700-800 daltons is disclosed. The factor can be isolated, using chromatographic methods, from cachexia-inducing tumors, cultures of tissue cells of cachexia-inducing tumors especially cultures of a MAC16 tumor cell line, or from body fluids such as serum or urine of mammals bearing cachexia-inducing tumors. Cancer diagnostic applications in relation to human individuals are described as well as uses for screening and identifying potential anti-cachetic and/or antitumor therapeutic agents.

Growing community of inventors

Warwickshire, United Kingdom

Michael John Tisdale